Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630473 | 0.85 | NR3C2 (0.41) | ALDH1A1PRMT5WDR77KMT2AHIF1A | |
| SCHEMBL4829107 | 0.85 | PRMT5 (0.40) | RAB9ASMN1; SMN2NPC1ALDH1A1PRMT5 | |
| SCHEMBL4836369 | 0.85 | PTGS2 (0.42) | RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A | |
| SCHEMBL4836837 | 0.84 | LMNA (0.46) | RAB9ASMN1; SMN2NPC1ALDH1A1PRMT5 | |
| SCHEMBL4831072 | 0.82 | MEN1 (0.44) | ALDH1A1PRMT5WDR77KMT2AKDM4E | |
| SCHEMBL4831559 | 0.81 | PDE2A (0.42) | ALDH1A1KDM4EHPGDPDE2ALMNA | |
| SCHEMBL27632007 | 0.81 | BPTF (0.40) | RAB9ASMN1; SMN2DUSP3L3MBTL1NPC1 | |
| SCHEMBL4833248 | 0.80 | CCNC (0.50) | RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A | |
| SCHEMBL4833261 | 0.80 | CCNC (0.50) | RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A | |
| SCHEMBL16194462 | 0.79 | ALDH1A3 (0.46) | KMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829010-B2 | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | HELAL CHRISTOPHER JOHN (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080806-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PDE12, PDE2A, CYP1A2 | RAB9A 1844/4885SMN1; SMN2 1173/4885DUSP3 920/4885 |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | RAB9A 4059/4885SMN1; SMN2 75/4885DUSP3 4531/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | RAB9A 4059/4885SMN1; SMN2 75/4885DUSP3 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.